WP
IRWD icon

Woodline Partners’s Ironwood Pharmaceuticals IRWD Stock Holding History

Woodline Partners’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,511,366
Closed -$15.6M – 193
2020
Q2 		$15.6M Buy
+1,511,366
New +$15.5M 0.62% 54

Other funds holding IRWD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Woodline Partners's IRWD Position: Q3 2020 in Review

Woodline Partners sold out of Ironwood Pharmaceuticals (IRWD) in Q3 2020, closing a stake of 1,511,366 shares — an estimated $15.6M sold.

Woodline Partners first reported a position in IRWD in Q2 2020 and held it in 1 quarter. The position peaked at $15.6M in Q2 2020. 190 funds tracked by Wall St. Rank hold IRWD as of Q3 2020.

  • Woodline Partners reported no remaining Ironwood Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Woodline Partners sold 1,511,366 Ironwood Pharmaceuticals shares in Q3 2020, an estimated $15.6M.
  • Woodline Partners first reported a position in Ironwood Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Woodline Partners's Ironwood Pharmaceuticals position peaked at $15.6M in Q2 2020.
  • 190 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q3 2020.

Based on Woodline Partners's 13F filing for Q3 2020, filed 16 Nov 2020.